FIGURE 3 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
crossref(2024)
摘要
Independence of B7-H3 expression and immunotherapy biomarkers. Alteration frequency of TMB-high (A), MSI-high (B), MMRd (C), and PD-1/ PD-L1 status (D) across 11 different cancer types with high and low B7-H3 expression, including prostate cancer from a primary site (PRAD-Prostate), prostate cancer from a metastatic site (PRAD-Metastatic), colorectal cancer with microsatellite stability (CRC-MSS), colorectal cancer with microsatellite instability (CRC-MSI), non–small cell lung adenocarcinoma (NSCLC-Ad), non–small cell lung squamous carcinoma (NSCLC-Sq), triple-negative breast cancer (BRCA-TNBC), hormone receptor–positive/HER2-negative breast cancer (BRCA-HR+/HER2−), HER2-positive breast cancer (BRCA-HER2+), ovarian surface epithelial carcinoma (OSEC), and pancreatic carcinoma (PDAC). *, q < 0.05; **, q < 0.01; ***, q < 0.001. Cox proportional HRs were calculated for each comparison group with significance determined as q values of <0.05 using log-rank statistics.
更多查看译文
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要